Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration

Purpose To report the short-term safety, biologic effect, and a possible mechanism of action of intravitreal bevacizumab in patients with neovascular age-related macular degeneration (AMD). Design Interventional, consecutive, retrospective case series. Participants Eighty-one eyes of 79 patients with subfoveal neovascular AMD. Methods Patients received intravitreal bevacizumab (1.25 mg) on a monthly basis until macular edema, subretinal fluid...